Multimodal MRI combined with RNA sequencing reveals pathological signatures in the 9-month-old 3×Tg-AD mouse brain

Probably not a substantial claim: may not pass S3 (load-bearing).

Cognitive impairment manifests at the age of 3 to 4 months in the 3×Tg-AD model.

“Cognitive impairment manifests at the age of 3 to 4 months.”

• cites Belfiore et al., 2019 sourceDisputed

  The Abstract says cognitive decline in the female 3xTg-AD mice studied was first apparent at 6 months, not 3–4 months. The Results section, “Learning and memory impairments in 3xTg-AD mice” (page unavailable), reports significant deficits at 6 months; the study tested mice at 2 and 6 months but not at 3–4 months. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

Within the hippocampus, significant changes of diffusion metrics (FA, MD, AxD, and RD) were observed in 3×Tg-AD mice compared with controls, with decreased FA and AxD at both 2 and 8 months, and increased RD at 12 and 14 months.

“Within the hippocampus, significant changes of diffusion metrics (FA, MD, AxD, and RD) were observed in 3×Tg-AD mice compared with controls, with decreased FA and AxD at both 2 and 8 months (Falangola et al., 2021), and increased RD at 12 and 14 months (Snow et al., 2017).”

• cites Falangola et al., 2021 sourceDisputed

  The Results (Group analysis; page unavailable) confirm significant hippocampal diffusion-metric differences at 2 and 8 months. But the Discussion (page unavailable) says all hippocampal diffusion-tensor metrics, including axial diffusivity, were significantly higher—not decreased—in 2-month-old 3xTg-AD mice. The 12- and 14-month RD finding is attributed to Snow et al., not this source. (LLM, conf=0.86)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites Snow et al., 2017 sourceDisputed

  The Snow citation is attached to the increased-RD finding. In the DTI measures and Discussion sections (pages unavailable), the paper reports a significant RadD increase in the slice containing the hippocampus, but explicitly says there was no difference within the hippocampal region itself. Its results group mice aged 12–14 months rather than reporting separate findings at 12 and 14 months. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

In the 3×Tg-AD model, intraneuronal amyloid-beta begins accumulating around 2 months of age while extracellular amyloid-beta deposits become apparent at 6 months.

“intraneuronal Aβ begins accumulating around 2 months of age while extracellular Aβ deposits become apparent at 6 months.”

• cites Belfiore et al., 2019 sourcePartly supported

  The Results section on age-dependent plaque accumulation (page unavailable) reports that extracellular Aβ plaques were absent at 2 months and first detected in the hippocampus at 6 months. It does not establish that intraneuronal Aβ begins accumulating around 2 months; a search for “intraneuronal” found no passage reporting that onset. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Age-related brain atrophy and myelin loss are observed on advanced high-field MRI in the 3×Tg-AD model.

“Alongside the progression of AD pathology, age-related brain atrophy and myelin loss are observed on advanced high-field MRI (Ni, 2021; Jullienne et al., 2022; Bergamino et al., 2023).”

• cites Ni, 2021Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Jullienne et al., 2022 sourcePartly supported

  Section 4.2.1 reports MRI-observed cortical atrophy in 18-month-old 3xTg-AD mice, and the Summary describes volumetric declines with increasing age. But section 4.2.4 reports no changes in myelin staining in mice aged 11–17 months; it does not support the claimed myelin loss. The supplied passages do not establish that these findings were observed specifically on high-field MRI (page numbers unavailable). (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites Bergamino et al., 2023 sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

The 3×Tg-AD mouse model possesses three gene mutations associated with human familial Alzheimer's disease: human presenilin-1 M146V, human amyloid precursor protein Swedish, and human tau protein P301L.

“One commonly used animal model of AD is the triple transgenic mouse model (3×Tg-AD), which possesses three gene mutations associated with human familial AD: the human presenilin-1 M146V mutation, human amyloid precursor protein Swedish mutation, and human tau protein P301L mutation (Chen et al., 2023; Li et al., 2025).”

• cites Chen et al., 2023 sourcePartly supported

  The discussion of the 3xTg model (p. 16) identifies the APP Swedish and PS1M146V mutations and the MAPTP301L tau transgene, supporting the list of three changes. It does not state that all three are human mutations associated with familial Alzheimer’s disease. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites Li et al., 2025Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

By 12 months of age, amyloid-beta deposits have spread extensively from the caudal hippocampus to other regions in the 3×Tg-AD model.

“By 12 months of age, Aβ deposits have spread extensively from the caudal hippocampus to other regions (Belfiore et al., 2019).”

• cites Belfiore et al., 2019 sourcePartly supported

  The Results section (page unavailable) reports plaques first in the caudal hippocampus, in all three hippocampal regions by 12 months, and first detectable in several cortical regions at 12 months. Calling the spread “extensive” by that age overstates the finding: the paper says plaques were present throughout the cortex at 20 months. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

In the 3×Tg-AD model, tau pathology becomes detectable around 6 months of age, and neurofibrillary tangles appear after 12 months.

“Tau pathology becomes detectable around 6 months of age, and neurofibrillary tangles appear after 12 months (Belfiore et al., 2019).”

• cites Belfiore et al., 2019 sourcePartly supported

  The Results section reports detectable tau phosphorylation in the hippocampus of female 3xTg-AD mice at 6 months. It does not establish that neurofibrillary tangles first appear after 12 months; the age-related findings concern phosphorylated-tau immunoreactivity, not tangle formation (page not provided). (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Similar DTI changes have been reported in other regions such as the fimbria, basal forebrain, external capsule, and internal capsule, characterized by decreased fractional anisotropy and axial diffusion and increased radial diffusion.

“Similar DTI changes have also been reported in other regions such as the fimbria, basal forebrain, external capsule, and internal capsule, characterized by decreased fractional anisotropy (FA) and axial diffusion (AxD) and increased radial diffusion (RD) (Falangola et al., 2020; Falangola et al., 2021; Ni, 2021; Bergamino et al., 2023).”

• cites Falangola et al., 2020 sourcePartly supported

  The Results (page unavailable) report decreased FA and increased radial diffusivity in the fimbria of 2-month-old 3×Tg-AD mice. They report decreased axial diffusivity in the corpus callosum, not the fimbria, and only kurtosis-metric decreases in the internal and external capsules. The reported results do not address the basal forebrain, so this source does not support the claimed pattern across all four named regions. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites Falangola et al., 2021 sourcePartly supported

  The Results (Group analysis; page unavailable) report lower fractional anisotropy and higher radial diffusivity in the fimbria of 3xTg-AD mice, but do not report lower axial diffusivity there. The Abstract (page unavailable) reports age-related decreases in fractional anisotropy and axial diffusivity in the basal forebrain, but an increase in radial kurtosis, not radial diffusivity. The Methods (DKI post-processing and Image analysis; page unavailable) list the studied regions as basal forebrain, hippocampus, fimbria, and fornix—not the external or internal capsule. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites Ni, 2021Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Alzheimer's disease is characterized by neuritic plaques and neurofibrillary tangles resulting from amyloid-beta accumulation, aggregation of fibrillar plaques, and hyperphosphorylation of tau protein.

“Previous studies of AD pathology have demonstrated that the disease is characterized by the presence of neuritic plaques and neurofibrillary tangles resulting from amyloid-beta (Aβ) accumulation, aggregation of fibrillar plaques, and hyperphosphorylation of tau protein (Depp et al., 2023; Zhang et al., 2023; Kovacs et al., 2024; Wang et al., 2024; Zhang et al., 2025).”

• cites Depp et al., 2023 sourcePartly supported

  The Main section states that AD pathology is characterized by Aβ plaques and neurofibrillary tangles, and the paper discusses increased amyloid deposition. It does not establish the sentence’s more specific description of neuritic and fibrillar plaques or explain the tangles through tau hyperphosphorylation. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites Zhang et al., 2023 sourcePartly supported

  The Introduction describes extracellular amyloid-β plaques and intracellular tau tangles as hallmark pathologies of Alzheimer’s disease. It does not specify that the plaques are neuritic or fibrillar, or explain the tangles through tau hyperphosphorylation. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites Kovacs et al., 2024 sourcePartly supported

  The Introduction (page unavailable) says AD neuropathologic change is classically characterized by amyloid-β and tau pathologies, including neurofibrillary tangles; the Discussion also mentions neuritic plaques. The paper does not establish the claim’s more specific account of fibrillar-plaque aggregation and tau hyperphosphorylation producing those lesions, and it describes cases with extensive amyloid deposition but little tau pathology. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Sample sizes were not predetermined using statistical methods, but were similar to those reported in previous publications.

“Sample sizes were not predetermined using statistical methods; however, our sample sizes are similar to those reported in previous publications (Manno et al., 2019; Rollins et al., 2019; Güell-Bosch et al., 2020).”

• cites Manno et al., 2019 sourceSupported
• cites Rollins et al., 2019 sourceSupported
• cites Güell-Bosch et al., 2020 sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

To avoid confounding effects of fluctuating ovarian hormones in females, only male mice were used.

“To avoid the confounding effects of fluctuating ovarian hormones in females (Beery and Zucker, 2011), nine male 3×Tg-AD mice on a C57BL/6J-congenic background (approximately 7 months old) and nine control mice weighing approximately 25 to 30 g were procured from Wuhan Youdu Biotechnology Company (Wuhan, China; license no. SCXK (E) 2021-0025).”

• cites Beery and Zucker, 2011 sourcePartly supported

  The Introduction describes concern that hormonal cycles can confound experiments, so the cited paper supports the existence of that concern. But the Recommendations say female rodents can be studied without estrous-cycle confounding through appropriate study design; the paper does not support using males only as a necessary way to avoid it. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

In a previous study of 3×Tg-AD mice, wider transcriptional changes triggered by abnormal amyloid-beta and neurofibrillary tangle deposition occurred well before behavioral decline.

“wider transcriptional changes triggered by the abnormal deposition of Aβ and neurofibrillary tangles occurred well before behavioral decline”

• cites Yin et al., 2020 sourceSupported

May combine two claims.

At around 9 months in the 3×Tg-AD model, neuroinflammation becomes evident and amyloid-beta deposition shifts from intraneuronal to extracellular.

“It is at this specific stage that neuroinflammation becomes evident and Aβ deposition shifts from intraneuronal to extracellular (Belfiore et al., 2019).”

• cites Belfiore et al., 2019 sourcePartly supported

  The Results sections on microgliosis and Aβ plaques report that microglial activation and extracellular plaques were first detected at 6 months in female 3xTg-AD mice, supporting the general progression described. The paper does not establish a shift from intraneuronal to extracellular deposition at around 9 months; it did not assess a 9-month group. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

DTI is a powerful noninvasive method widely used for detecting brain microstructural abnormalities associated with Alzheimer's disease.

“DTI is a powerful noninvasive method widely used for detecting brain microstructural abnormalities associated with AD (Kantarci et al., 2017; Falangola et al., 2020; Bergamino et al., 2023).”

• cites Kantarci et al., 2017 sourceSupported
• cites Falangola et al., 2020 sourcePartly supported

  The Introduction describes diffusion MRI (dMRI) as a powerful, widely used noninvasive tool for detecting AD-associated white-matter changes. It identifies DTI as one dMRI technique, but the broad statement is about dMRI, not DTI specifically; the study primarily uses DKI and diffusion-tensor measures. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites Bergamino et al., 2023 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Prior research has demonstrated that gene expression distribution can be mapped onto functional MRI.

“Prior research has demonstrated that gene expression distribution can be mapped onto functional MRI (Lachmann et al., 2018).”

• cites Lachmann et al., 2018 sourceCould not verify

  The Discussion (page unavailable) says the resource calculates gene-expression distributions across tissues and cell lines. Our copy does not say those distributions were mapped onto functional MRI; searches for fMRI and functional magnetic resonance imaging found no passage addressing that link. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

In that previous study, genes specifically associated with abnormal amyloid-beta protein deposition and cognitive decline were identified.

“genes specifically associated with abnormal Aβ protein deposition and cognitive decline were identified (Yin et al., 2020).”

• cites Yin et al., 2020 sourceSupported

Classified as probably not a substantial claim. May combine two claims.

RNA sequencing is an effective method for serial analysis of gene expression, which aids in understanding regulation mechanisms.

“RNA sequencing (RNA-seq) is an effective method for serial analysis of gene expression, which aids in understanding regulation mechanisms (Lachmann et al., 2018).”

• cites Lachmann et al., 2018 sourcePartly supported

  The Introduction (page unavailable) describes RNA-seq as a common, sensitive method for quantifying gene expression. The Results section on predicting biological functions and protein interactions (page unavailable) uses expression data to predict upstream regulatory transcription factors, supporting a link to studying regulation. The paper does not describe serial or longitudinal analysis of gene expression. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

At the preclinical stage of AD, parahippocampal gyrus atrophy has been detected in patients with mild cognitive impairment.

“At the preclinical stage of AD, parahippocampal gyrus atrophy has also been detected in patients with mild cognitive impairment (Huang et al., 2023).”

• cites Huang et al., 2023 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

A previous study in a mouse model of AD reported lower volumes in the right stria terminalis at 6 months of age.

“A previous study in a mouse model of AD reported lower volumes in the right stria terminalis at 6 months of age (Rollins et al., 2019).”

• cites Rollins et al., 2019 sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

AD is characterized by progressive memory loss and cognitive dysfunction, and age-dependent decline in neurogenesis may compromise the structure and function of the hippocampus over time, leading to susceptibility to memory impairment.

“AD is characterized by progressive memory loss and cognitive dysfunction, and age-dependent decline in neurogenesis may compromise the structure and function of the hippocampus over time, leading to susceptibility to memory impairment (Hollands et al., 2016).”

• cites Hollands et al., 2016 sourceSupported

• AssumptionRests on an assumption: The 3×Tg-AD mouse model at 9 months of age recapitulates key aspects of human AD pathology relevant to the study's conclusions.

Probably not a substantial claim: may not pass S3 (load-bearing).

Longitudinal studies have revealed significant changes in brain volumes (both increases and decreases) in 3×Tg-AD mice during the early stages from 1.5 months to 6 months of age.

“Longitudinal studies have revealed significant changes in brain volumes (both increases and decreases) in 3×Tg-AD mice during the early stages from 1.5 months to 6 months of age (Kong et al., 2018; Rollins et al., 2019).”

• cites Kong et al., 2018 sourceNot checked — no full text of the source
• cites Rollins et al., 2019 sourcePartly supported

  The Results (Fig. 5) report significant increases and decreases in local brain volume in 3xTg-AD mice over time. However, Magnetic resonance image acquisition specifies measurements at 8, 16, and 24 weeks of age—approximately 2 to 6 months—not from 1.5 months. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Previous DTI studies have demonstrated WM integrity impairment in various types of AD mouse models.

“Previous DTI studies have demonstrated WM integrity impairment in various types of AD mouse models (Qin et al., 2013; Massalimova et al., 2020; Bergamino et al., 2023).”

• cites Qin et al., 2013 sourceNot checked — no full text of the source
• cites Massalimova et al., 2020 sourcePartly supported

  The Discussion/Conclusion (p. 8) reports DTI-detected white-matter changes in homozygous P301L mice, supporting the white-matter impairment attributed to this study. The paper identifies P301L as a model of human tauopathy, not specifically an AD mouse model, and reports no comparable changes in hemizygous mice. The other citations may address the sentence’s reference to various models, but this source alone does not establish that breadth. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites Bergamino et al., 2023 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The olfactory bulb is affected early in AD, playing an important role in the onset and progression of the disease.

“The OLF is affected early in AD, playing an important role in the onset and progression of the disease (Zhou et al., 2024).”

• cites Zhou et al., 2024 sourceCould not verify

  The Introduction and Discussion address early AD-related changes in the hippocampus, particularly iron deposition, but do not address the olfactory bulb. Searches for “olfactory bulb,” “OLF,” and early olfactory involvement in AD found no passage supporting the claim. Page numbers were not available in our copy. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Acquisition of spatial search strategies and reversal learning in the MWM depend on functional connectivity of the hippocampus.

“A study combining neuroimaging and behavior found that acquisition of spatial search strategies and reversal learning in the MWM depend on functional connectivity of the hippocampus (Shah et al., 2019).”

• cites Shah et al., 2019 sourcePartly supported

  The Discussion (page unavailable) describes hippocampal connections as important during acquisition and reports hippocampal connectivity after reversal learning. The results also link hippocampal connectivity with spatial strategies after reversal. However, the study reports associations across broader brain networks, not a demonstrated dependence of both learning processes specifically on hippocampal connectivity. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

A prior investigation discovered decreased AxD and FA values within the basal forebrain of 2-month-old 3×Tg-AD mice, with progressive temporal declines in AxD and FA at 8 and 15 months of age.

“For instance, a prior investigation discovered decreased AxD and FA values within the basal forebrain of 2-month-old 3×Tg-AD mice, with progressive temporal declines in AxD and FA at 8 and 15 months of age (Falangola et al., 2021).”

• cites Falangola et al., 2021 sourcePartly supported

  The Discussion reports lower basal-forebrain D∥ (AxD) and FA in 2-month-old 3xTg-AD mice than in controls, and lower values for both metrics at 8 months. However, the Results (Age-related trajectories; page unavailable) report no significant basal-forebrain changes between 8 and 15 months, so the claimed progressive decline through 15 months is not supported. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Previous studies have demonstrated significant functional and structural changes in the hippocampus in AD, which are likely due to impaired neurogenesis.

“Previous studies have demonstrated significant functional and structural changes in the hippocampus in AD, which are likely due to impaired neurogenesis (Mu and Gage, 2011; Chiquita et al., 2019).”

• cites Mu and Gage, 2011 sourcePartly supported

  The Abstract describes early hippocampal damage in AD and says altered neurogenesis may contribute to neuronal vulnerability and memory impairment. But it explicitly states that causal links have not been established, while the Conclusions note both increased and decreased neurogenesis across studies. The source therefore does not establish that hippocampal functional and structural changes are likely due to impaired neurogenesis. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites Chiquita et al., 2019 sourcePartly supported

  The Discussion reports hippocampal structural differences and recognition-memory impairment in 3xTg-AD mice, and notes evidence of hippocampal atrophy in AD patients. It does not attribute these changes to impaired neurogenesis; the proposed mechanism in the cited discussion is intraneuronal Aβ accumulation. The paper’s direct findings are also in a mouse model, not patients with AD. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

• AssumptionRests on an assumption: The 3×Tg-AD mouse model at 9 months of age recapitulates key aspects of human AD pathology relevant to the study's conclusions.

Probably not a substantial claim: may not pass S3 (load-bearing).

Previous neuroimaging studies comparing GM changes between AD patients and healthy individuals have identified significant morphological atrophy in the hippocampus, entorhinal cortex, amygdala, putamen, and thalamus.

“Previous neuroimaging studies comparing GM changes between AD patients and healthy individuals have identified significant morphological atrophy in the hippocampus, entorhinal cortex, amygdala, putamen, and thalamus (de Jong et al., 2008; Serra et al., 2010; Matsuda, 2013).”

• cites de Jong et al., 2008 sourcePartly supported

  The Abstract and Discussion report significantly smaller hippocampal, putaminal, and thalamic volumes in patients with probable Alzheimer’s disease; the Introduction also reports earlier imaging evidence of amygdalar atrophy. Our copy does not identify entorhinal cortex atrophy specifically. The study compared patients with memory complainers rather than a group described simply as healthy individuals. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites Serra et al., 2010 sourceNot checked — no full text of the source
• cites Matsuda, 2013Not checked — no full text of the source

May combine two claims.

Previous studies on 3×Tg-AD mice have reported significant volumetric decreases and WM microstructural abnormalities in the corpus callosum and internal capsule compared with controls.

“Previous studies on 3×Tg-AD mice have reported significant volumetric decreases (Kong et al., 2018) and WM microstructural abnormalities (Praet et al., 2018; Gatto et al., 2019; Bergamino et al., 2023) in the CC and internal capsule compared with controls.”

• cites Kong et al., 2018 sourceNot checked — no full text of the source
• cites Praet et al., 2018 sourcePartly supported

  The Results (ROI-based analysis; page unavailable) report significantly reduced fractional anisotropy in parts of the corpus callosum compared with wild-type controls, supporting a white-matter microstructural abnormality. However, the Methods identify the mice as APP/PS1, not 3×Tg-AD, and the cited passages do not report an internal-capsule finding. The volumetric-decrease claim is cited to Kong et al., not Praet et al., and is not assessed here. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites Gatto et al., 2019 sourcePartly supported

  The Results and Discussion report white-matter microstructural abnormalities in the corpus callosum compared with controls. But the mice studied were R6/2 Huntington’s disease mice, not 3×Tg-AD mice, and these passages do not report abnormalities in the internal capsule. The volumetric-decrease portion of the citing sentence is attributed to Kong et al., not to this source. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The Wnt signaling pathway inhibited oligodendrocyte differentiation and maturation while exerting a negative regulatory role in myelin development.

“In a previous study, the Wnt signaling pathway inhibited oligodendrocyte differentiation and maturation while exerting a negative regulatory role in myelin development (Boccazzi et al., 2023).”

• cites Boccazzi et al., 2023 sourcePartly supported

  The Abstract (p. 3) reports that high WNT tone impaired oligodendrocyte differentiation, and the Results (p. 9) link WNT activation to maturation arrest and reduced MBP expression. The Introduction (p. 3), however, says WNT’s roles in myelination depend on CNS region and developmental stage; it does not support an unqualified negative regulatory role in myelin development. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Mek1 is an upstream component of the MAPK signaling pathway that can enhance myelin growth.

“Mek1 is an upstream component of the MAPK signaling pathway that can enhance myelin growth (Ishii et al., 2021).”

• cites Ishii et al., 2021 sourceSupported

May combine two claims.

Bulk RNA-seq revealed differential expression of 1389 genes between the two groups, with 774 genes up-regulated and 615 genes down-regulated in the 3×Tg-AD group.

“The findings revealed differential expression of 1389 genes between the two groups, with 774 genes up-regulated and 615 genes down-regulated in the 3×Tg-AD group (Figure 8A and B).”

May combine two claims.

In the open field test, there were no significant differences in distance traveled or speed between 9-month-old 3×Tg-AD mice and controls.

“The open field test assessed locomotor activity, revealing no significant differences in distance traveled or speed between the 3×Tg-AD mice and controls (Figure 1A).”

May combine two claims.

Compared with controls, 9-month-old 3×Tg-AD mice exhibited a significant decrease in gray matter volume primarily in the bilateral hippocampi, right retrohippocampal region, right subparafascicular area of thalamus, bilateral primary somatosensory area, left caudoputamen, left primary motor area, right anterolateral visual area, anterior cingulate area, and olfactory bulb (P < 0.05 with familywise

“Compared with the control group, the 3×Tg-AD group exhibited a significant decrease in GM volume, primarily in the bilateral hippocampi, right retrohippocampal region, right subparafascicular area of thalamus, bilateral primary somatosensory area, left caudoputamen (CP), left primary motor area, right anterolateral visual area, anterior cingulate area, and olfactory bulb (OLF).”

• Also stated in: § Voxel-based morphometry analysis of gray matter and white matter volumes · plain

  “The GM volume in the 3×Tg-AD group was markedly lower than that in the control group.”

May combine two claims.

Mice with lower Y-maze alteration exhibited reduced GM volume, decreased FA, increased MD, and elevated RD within the hippocampus.

“This study revealed that mice with lower Y-maze alteration exhibited reduced GM volume, decreased FA, increased MD, and elevated RD within the hippocampus.”

• AssumptionRests on an assumption: MRI metrics (GM volume, FA, MD, RD) are valid indices of brain microstructure and pathology in this model.

May combine two claims.

Memory impairment occurs alongside depressive-like behavior exhibited by these mice.

“Consequently, memory impairment occurs alongside depressive-like behavior exhibited by these mice.”

• AssumptionRests on an assumption: The 3×Tg-AD mouse model at 9 months of age recapitulates key aspects of human AD pathology relevant to the study's conclusions.

Classified as probably not a substantial claim. May combine two claims.

Previous studies have demonstrated the feasibility of combining imaging and genomics analysis, which could lead to a better understanding of the behavioral and pathological changes in Alzheimer's disease.

“Such previous studies have demonstrated the feasibility of combining imaging and genomics analysis, which could lead to a better understanding of the behavioral and pathological changes in AD.”

Classified as probably not a substantial claim.

VBM is an automated technique that allows for examination of brain anatomy differences between groups at a voxel-wise level without requiring predefined regions of interest.

“VBM is an automated technique that allows for the examination of brain anatomy differences between groups at a voxel-wise level without requiring predefined regions of interest (ROIs) (Good et al., 2001).”

• cites Good et al., 2001 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Behavioral tests were conducted by two trained and experienced observers who were blinded to the treatment conditions.

“The behavioral tests were conducted by two trained and experienced observers who were blinded to the treatment conditions.”

Probably not a substantial claim: may not pass S3 (load-bearing).

A previous DTI study did not observe any changes in diffusion metrics or alterations in myelin staining or white matter volumes across mice aged from 11 to 17 months.

“However, a previous DTI study did not observe any changes in diffusion metrics or alterations in myelin staining or WM volumes across mice aged from 11 to 17 months (Kastyak-Ibrahim et al., 2013).”

• cites Kastyak-Ibrahim et al., 2013 sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

Control mice were wild type non-transgenic SPF-grade animals of the same sex, age, and weight as the 3×Tg-AD mice.

“The control mice were wild type non-transgenic SPF-grade animals of the same sex, age, and weight as the 3×Tg-AD mice.”

Probably not a substantial claim: may not pass S3 (load-bearing).

One study involving mice aged between 11 and 17 months found no WM DTI changes compared with controls.

“One study involving mice aged between 11 and 17 months found no WM DTI changes compared with controls (Kastyak-Ibrahim et al., 2013).”

• cites Kastyak-Ibrahim et al., 2013 sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

GM degeneration leads to microstructural abnormality through demyelination in the hippocampus and striatum-like amygdala nuclei.

“One explanation for these diffusion metric changes in the hippocampus and sAMY is that GM degeneration leads to microstructural abnormality through demyelination.”

Probably not a substantial claim: may not pass S3 (load-bearing).

A previous neuroimaging study showed that olfactory impairment is associated with hippocampal atrophy and entorhinal cortical thinning in preclinical AD.

“A previous neuroimaging study showed that olfactory impairment is associated with hippocampal atrophy and entorhinal cortical thinning in preclinical AD (Hagan, 2023).”

• cites Hagan, 2023 sourceNot checked — no full text of the source

May combine two claims.

The directionality of DTI metrics observed in this study is generally consistent with most previous findings and highlights that outcomes are dependent on both age and region location within the model.

“The directionality of DTI metrics observed in our study is generally consistent with most previous findings and highlights that outcomes are dependent on both age and region location within the model.”

Probably not a substantial claim: may not pass S2 (checkable).

Modulation of these pathways holds potential therapeutic value for AD.

“These results suggest that modulation of these pathways holds potential therapeutic value for AD.”

• AssumptionRests on an assumption: The RNA-seq data from hippocampus reflects gene expression relevant to the MRI and behavioral changes.

May combine two claims.

These findings support the potential utilization of brain volume and diffusion metrics as biomarkers for AD pathology, which could be applied in the clinical diagnosis of AD in humans.

“These findings support the potential utilization of brain volume and diffusion metrics as biomarkers for AD pathology, which could be applied in the clinical diagnosis of AD in humans.”

• AssumptionRests on an assumption: The 3×Tg-AD mouse model at 9 months of age recapitulates key aspects of human AD pathology relevant to the study's conclusions.
• AssumptionRests on an assumption: MRI metrics (GM volume, FA, MD, RD) are valid indices of brain microstructure and pathology in this model.

Probably not a substantial claim: may not pass S3 (load-bearing).

The small number of mice reduced the statistical power of the analysis.

“The small number of mice reduced the statistical power of the analysis.”

• AssumptionRests on an assumption: The 3×Tg-AD mouse model at 9 months of age recapitulates key aspects of human AD pathology relevant to the study's conclusions.

May combine two claims.

Our study focused exclusively on male 3×Tg-AD mice, and all the differences observed in our results are based on this condition.

“It is important to note that our study focused exclusively on male 3×Tg-AD mice, and all the differences observed in our results are based on this condition.”

• AssumptionRests on an assumption: The 3×Tg-AD mouse model at 9 months of age recapitulates key aspects of human AD pathology relevant to the study's conclusions.

Probably not a substantial claim: may not pass S3 (load-bearing).

The suboptimal DTI sequence parameters may account for our inability to achieve family-wise error correction during DTI data analysis.

“This aspect may account for our inability to achieve family-wise error correction during DTI data analysis.”

• AssumptionRests on an assumption: DTI has technical limitations in accurately describing intricate GM geometry and WM microstructural change.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The DTI sequence parameters used in this study, including the b-value and the slice-to-in-plane resolution ratio, are suboptimal and require further optimization in future investigations.

“Third, the DTI sequence parameters used in this study, including the b-value and the slice-to-in-plane resolution ratio, are suboptimal and require further optimization in future investigations.”

• AssumptionRests on an assumption: DTI has technical limitations in accurately describing intricate GM geometry and WM microstructural change.

Probably not a substantial claim: may not pass S3 (load-bearing).

Women often experience accelerated cognitive decline despite a similar or lower amyloid burden compared with men.

“Clinical evidence of sex-specific cognitive trajectories in AD further supports this distinction, as women often experience accelerated cognitive decline despite a similar or lower amyloid burden compared with men (Laws et al., 2018).”

• cites Laws et al., 2018 sourceNot checked — no full text of the source

• AssumptionRests on an assumption: The 3×Tg-AD mouse model at 9 months of age recapitulates key aspects of human AD pathology relevant to the study's conclusions.